News & Press releases

Update on major activities on this page. Follow further updates on our Linkedin page

july 2022

U.S. Patent to Protect More Efficient Buprenorphine Production

River Stone Biotech Inc. Announces Issuance of U.S. Patent to Protect Their More Efficient Buprenorphine Production Process.

may 2022

Strategic Update

River Stone Biotech Inc. participates in DCAT 2022  conference and announces its ambition in becoming a global provider of substance abuse APIs.

nov 2021

Series B Fundraise Closes

River Stone Biotech Inc. Announces $6.8M Series B Financing to Advance Lead Pipeline Projects. Goal: To Treat Opiate Use Disorder and Opiate Overdose